NVCT logo

Nuvectis Pharma Inc. (NVCT)

$19.11

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NVCT

Market cap

$657172032

EPS

-1.89

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

-0.210857

Price on NVCT

Previous close

$20.24

Today's open

$20

Day's range

$18.63 - $20

52 week range

$5.77 - $29.28

Profile about NVCT

CEO

Ron Bentsur

Employees

16

Headquarters

Fort Lee, NJ

Exchange

NASDAQ Capital Market

Shares outstanding

34388908

Issue type

Common Stock

NVCT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on NVCT

Nuvectis Pharma Q3 Earnings Call Highlights

Nuvectis Pharma NASDAQ: NVCT said its third quarter marked a strategic shift into late-stage development following a licensing agreement with Haisco for ex-China rights to two drug candidates: ciprocopan, also known as NXP100, and NXP200.

news source

MarketBeat • Nov 4, 2026

news preview

Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript

Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights

In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. The Company's lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor (CFBi) for once-daily oral administration, was approved in China in July 2026 for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously untreated with complement inhibitors.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026

Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that it will host a conference call and webcast on Wednesday, November 4, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas

Single-agent NXP200 was administered to 27 patients with recurrent or progressive gliomas (20 with high-grade and 7 with low-grade). The objective response rate (ORR) based on Response Assessment in Neuro-Oncology criteria (RANO) 2.0 was 40.0% (8/20) in high-grade glioma, including 3 Complete Responses (CRs), and 42.9% (3/7) in low-grade glioma, including 1 CR.

news source

GlobeNewsWire • Oct 26, 2026

news preview

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.

news source

GlobeNewsWire • Oct 9, 2026

news preview

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, announced today that NXP200 (HSK42360), an oral, brain-penetrant, paradox-breaker BRAF inhibitor, has been granted Breakthrough Therapy Designation (BTD) for the treatment of patients with BRAF V600-mutant, recurrent or progressive high-grade glioma by China's Center for Drug Evaluation (CDE).

news source

GlobeNewsWire • Sep 24, 2026

news preview

Nuvectis Pharma To Participate in Upcoming Investor Conferences

Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET.

news source

GlobeNewsWire • Sep 3, 2026

news preview

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.

news source

Zacks Investment Research • Aug 19, 2026

news preview

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today reported its financial results for the second quarter of 2026 and provided an update on recent business progress.

news source

GlobeNewsWire • Aug 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Nuvectis Pharma Inc.

Open an M1 investment account to buy and sell Nuvectis Pharma Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NVCT on M1